🇺🇸 FDA
Pipeline program

Orforglipron

18566

Phase 3 small_molecule completed

Quick answer

Orforglipron for Type 2 Diabetes is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly and Company
Indication
Type 2 Diabetes
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials